NCT02643303
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02643303
Title A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Indications
kidney cancer
melanoma
sarcoma
breast cancer
Advanced Solid Tumor
head and neck squamous cell carcinoma
Merkel cell carcinoma
urinary bladder cancer
primary cutaneous T-cell non-Hodgkin lymphoma
Therapies
Durvalumab + Poly ICLC
Tremelimumab
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Research Facility Atlanta Georgia 30322 United States Details
Research Facility Lebanon New Hampshire 03756 United States Details
Research Facility Buffalo New York 14263 United States Details
Research Facility New York New York 10029 United States Details
Research Facility Cleveland Ohio 44195 United States Details
Research Facility Toledo Ohio 43614 United States Details
Research Facility Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field